Skip to content

Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations

Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02578303
Acronym
VAAPS
Enrollment
139
Registered
2015-10-16
Start date
2015-05-31
Completion date
2022-01-01
Last updated
2020-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Keywords

sleep apnea, phase-contrast MRI, cerebral blood flow, vascular risk factor, dementia

Brief summary

Obstructive sleep apnea syndrome (OSAS) is a sleep-disordered breathing characterized by the occurrence of repeated upper airway obstructions leading to airflow reduction (hypopnea) or cessation (apnea). The apnea-hypopnea index (AHI) is the number of apneas and hypopneas per hour of sleep. OSA patients often report cognitive complaints. About 25% of the elderly population is affected by this syndrome with a drastic increase of this rate among dementia patients. OSAS is considered to be an important risk factor for the development of hypertension, heart disease and stroke.

Detailed description

Numerous studies pointed out the close relationship between sleep apnea and cognitive impairment. To the investigators' knowledge, no trials have assessed the existence of a relationship between the IAH index and the cerebral arterial blood flow rate (macrocirculation). Developments in magnetic resonance imaging (MRI) provide new insights into the quantitative study of blood flow through phase contrast MRI also called flow MRI. The main hypothesis tested in this study is the existence of a relationship between OSAS and total cerebral arterial vascular inflow measured by PC-MRI (in mL/min) in the elderly population. * Primary outcome: The apnea/hypopnea index (measured by nocturnal respiratory polygraphy) and total arterial flow rate (measured by PC-MRI) * Secondary outcomes: 1. Measurement of arrhythmia 2. Measurement of arterial blood pressure

Interventions

OTHERVascular flow measurement by PC-MRI

participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels

Sponsors

Central Hospital Saint Quentin
Lead SponsorOTHER_GOV

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
75 Years to 120 Years
Healthy volunteers
Yes

Inclusion criteria

1. Elderly patients about or over 75 years 2. Any gender 3. Dementia Group: 3.1. MMSE (Mini Mental State Examination)\> 15 3.2. Diagnosis of dementia established according to DSM-IV 3.3. Dementia of the Alzheimer type from NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association) 4. Control Group: Preserved cognitive function corresponding to a normal MMSE score by the standards of Poitrenaud 5. Ability to understand and give consent freely (for demented subjects, a legal representative will be delegate)

Exclusion criteria

1. Elderly patients under 75 years 2. Anyone with a classic contraindication to MRI 2.1 Major behavioral disorders that do not allow the realization of MRI in optimal conditions 2.2 Claustrophobia 2.3 Presence of foreign non-compliant material 2.4 Presence of intraocular metal body 3. Having a history of chest surgery or neurosurgical 4. Chronic respiratory failure 5. Suffering from dementia other than that associated with Alzheimer's disease 6. Patients with a handicap 7. Patients under legal protection

Design outcomes

Primary

MeasureTime frame
Total arterial flowrate (measured by PC-MRI debit ml/Mn)at day 1 after inclusion

Secondary

MeasureTime frame
sleep apnea measured by elderly polygraphy (Number of apneas / night)at day 1 after inclusion up to 24 heures

Countries

France

Contacts

Primary ContactATTIER Jadwiga, MD
j.attier@ch-stquentin.fr0033323067216
Backup ContactBOULANOPUAR Abdelkrim, CRA
a.boulanouar@ch-stquentin.fr0033323067861

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026